MoneyWorks4Me

Tech Mahindra planning to start trials for COVID drug in next three to four months

11 Aug 2021 Evaluate

Tech Mahindra is planning to start trials for a COVID drug in the next three to four months after receiving the patent for a particular molecule. Markers Lab, the research and development arm of the IT company, is working on developing the drug. The company along with Reagene Biosciences has filed for a patent for a molecule that can be used to develop a drug against coronavirus.

Tech Mahindra represents the connected world, offering innovative and customer-centric information technology experiences, enabling Enterprises, Associates and the Society to Rise.

Tech Mahindra Share Price

1649.90 14.90 (0.91%)
07-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
TCS 2453.70
Infosys 1173.10
HCL Technologies 1348.90
Wipro 186.70
Tech Mahindra 1649.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: